An Updated Analysis of the Survival Endpoints of ASCENDE-RT
International Journal of Radiation Oncology*Biology*Physics · 2023-04 · 115 (5) · 1061-1070
DOI: 10.1016/j.ijrobp.2022.11.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023-04. Verfasst von Justin Oh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, BC Cancer - Vancouver, Vancouver, British Columbia, Canada; Department of Surgery, Faculty of Medicine, University …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Using the primary endpoint of time to biochemical progression (TTP), Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) randomized National Comprehensive Cancer Network patients with intermediate and high-risk prostate cancer to low-dose-rate brachytherapy boost (LDR-PB) or dose-escalated external beam boost (DE-EBRT). Randomization to the LDR-PB arm resulted in a 2-fold reduction in biochemical progression compared with the DE-EBRT group at a median follow-up of 6.5 years (P < .001). Herein, the primary endpoint and secondary survival endpoints of the ASCENDE-RT trial are updated at a 10-year median follow-up. METHODS: Patients were randomly assigned to either the LDR-PB or the DE-EBRT arm (1:1). All patients received 1 year of androgen deprivation therapy and 46 Gy in 23 fractions of pelvic RT. Patients in the DE-EBRT arm received an additional 32 Gy in 16 fractions, and those in the LDR-PB arm received an 125I implant prescribed to a minimum peripheral dose of 115 Gy. Two hundred patients were randomized to the DE-EBRT arm and 198 to the LDR-PB arm. RESULTS: The 10-year Kaplan-Meier TTP estimate was 85% ± 5% for LDR-PB compared with 67% ± 7% for DE-EBRT (log rank P < .001). Ten-year time to distant metastasis (DM) was 88% ± 5% for the LDR-PB arm and 86% ± 6% for the DE-EBRT arm (P = .56). There were 117 (29%) deaths. Ten-year overall survival (OS) estimates were 80% ± 6% for the LDR-PB arm and 75% ± 7% for the DE-EBRT arm (P = .51). There were 30 (8%) patients who died of prostate cancer: 12 (6%) in the LDR-PB arm, including 2 treatment-related deaths, and 18 (9%) in the DE-EBRT arm. CONCLUSIONS: Men randomized to the LDR-PB boost arm of the ASCENDE-RT trial continue to experience a large advantage in TTP compared with those randomized to the DE-EBRT arm. ASCENDE-RT was not powered to detect differences in its secondary survival endpoints (OS, DM, and time to prostate cancer-specific death) and none are apparent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, BC Cancer - Vancouver, Vancouver, British Columbia, Canada; Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Radiation Oncology, BC Cancer - Vancouver, Vancouver, British Columbia, Canada; Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic a…
- Department of Radiation Oncology, BC Cancer - Victoria, Victoria, British Columbia, Canada.
- Department of Radiation Oncology, BC Cancer - Kelowna, Kelowna, British Columbia, Canada.
- Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Department of Population Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Zitieren
APA
Oh, J., Tyldesley, S., Pai, H., McKenzie, M., Halperin, R., Duncan, G., Morton, G., Keyes, M., Hamm, J., & Morris, W. J. (2023). An Updated Analysis of the Survival Endpoints of ASCENDE-RT. International Journal of Radiation Oncology*Biology*Physics, 115(5), 1061-1070. https://doi.org/10.1016/j.ijrobp.2022.11.005
Vancouver
Oh J, Tyldesley S, Pai H, McKenzie M, Halperin R, Duncan G, et al. An Updated Analysis of the Survival Endpoints of ASCENDE-RT. International Journal of Radiation Oncology*Biology*Physics. 2023;115(5):1061-1070. doi:10.1016/j.ijrobp.2022.11.005
BibTeX
@article{Oh2023,
author = {Oh, Justin and Tyldesley, Scott and Pai, Howard and McKenzie, Michael and Halperin, Ross and Duncan, Graeme and Morton, Gerard and Keyes, Mira and Hamm, Jeremy and Morris, W James},
title = {An Updated Analysis of the Survival Endpoints of ASCENDE-RT},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2023},
volume = {115},
number = {5},
pages = {1061--1070},
doi = {10.1016/j.ijrobp.2022.11.005}
}
EUVIMED